Company Filing History:
Years Active: 2015-2016
Title: The Innovations of Ming-Jiu Chen
Introduction
Ming-Jiu Chen is a notable inventor based in Shrewsbury, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Ming-Jiu Chen's latest patents include the development of therapeutic DLL4 binding proteins. These DLL4 binding proteins encompass antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments. They are designed to bind DLL4 with high affinity and neutralize DLL4 and/or VEGF activity. The therapeutic applications of these proteins are particularly relevant for treating or preventing cancers and tumors, especially in the context of tumor angiogenesis.
Career Highlights
Ming-Jiu Chen is currently employed at AbbVie Inc., where he continues to advance his research and innovations. His work has positioned him as a key figure in the biotechnology sector, contributing to the development of therapies that have the potential to improve patient outcomes.
Collaborations
Ming-Jiu Chen collaborates with several esteemed colleagues, including Chung-Ming Hsieh and Jijie Gu. These partnerships enhance the research and development efforts within his field, fostering innovation and progress.
Conclusion
Ming-Jiu Chen's contributions to biotechnology, particularly through his patents on DLL4 binding proteins, highlight his role as an influential inventor. His work not only advances scientific knowledge but also holds promise for future cancer therapies.